WASHINGTON — Sodium thiosulfate, administered before and after reperfusion for STEMI, did not improve infarct size between 4 months and 2 years compared with placebo, a speaker reported.

Sodium thiosulfate showed no benefits for reducing injury to damaged areas of heart muscle following a heart attack, in a study presented at the American College of Cardiology’s 71st Annual ...

Sodium thiosulfate showed no benefits for reducing injury to damaged areas of heart muscle following a heart attack, in a study presented at the American College of Cardiology's 71st Annual ...

Vials of drug Currently, there is no approved therapy for calciphylaxis. Intravenous sodium thiosulfate does not improve skin lesions or reduce the risk of dying from calciphylaxis, a rare but ...

Sodium thiosulfate appeared associated with a decreased risk for ototoxic effects when administered during platinum-based chemotherapy, according to results of a study published in JAMA Network ...

The clinical trial evidence for anhydrous sodium thiosulfate is from 2 phase 3, open-label, randomised controlled trials comparing cisplatin-based chemotherapy plus anhydrous sodium thiosulfate with ...

The analysts forecast the global sodium thiosulfate market to exhibit a CAGR of 2.89% during the period 2019-2024.The report covers the present scenario and the growth prospects of the global sodium ...

In 33% of children in the cisplatin-sodium thiosulfate group and 63% in the cisplatin-alone group, hearing loss of grade 1 or higher occurred, which indicated a 48% lower incidence of hearing loss ...

The FDA has approved Pedmark (sodium thiosulfate) to reduce the risk of ototoxicity associated with cisplatin.

This makes sodium thiosulfate the first and only FDA-approved treatment for this indication and patient population.